Treatment 9 min
Hormone therapy for breast cancer: who needs it, which, how long
Who needs hormone therapy, how tamoxifen differs from aromatase inhibitors, how many years treatment lasts and how to cope with the side effects.
Written and medically reviewed by
Dr. Tara EinullaevaMedical oncologist, 9 years in practice. Credentials · reviewed 16 October 2026
Hormone therapy is given for breast cancer whose cells have receptors for estrogen (ER) and/or progesterone (PR). These tumors use female hormones as a signal to grow, and treatment either blocks that signal or lowers estrogen levels. It is one of the longest parts of treatment — usually at least 5 years — and how regularly you take the drug directly affects how well it works.
Who needs hormone therapy
The decision is based on immunohistochemistry (IHC) testing of the tumor. If the report says the tumor is ER- and/or PR-positive, hormone therapy is usually part of the plan. If there are no receptors, hormone therapy doesn’t work. I explain how to read these results in detail in the article on IHC in breast cancer.
Most breast cancers are like this: according to the US National Cancer Institute (NCI), about 80% of breast cancers are hormone receptor-positive.
Hormone therapy is used in different situations:
- after surgery (adjuvant) — to lower the risk of recurrence;
- sometimes before surgery (neoadjuvant) — to shrink the tumor; more on the logic of treatment before and after surgery in a separate article;
- in metastatic disease — as the backbone of treatment, often combined with targeted drugs.
Tamoxifen or aromatase inhibitors
The key question in choosing a drug is menopausal status.
| Tamoxifen | Aromatase inhibitors (letrozole, anastrozole, exemestane) | |
|---|---|---|
| How it works | Blocks estrogen receptors in cancer cells | Reduce estrogen production in fat and other tissues |
| Who for | Before and after menopause | After menopause; before menopause — only together with ovarian suppression |
| Common side effects | Hot flashes, vaginal discharge, changes to periods | Joint pain and stiffness, hot flashes, reduced bone density |
| Serious risks | Blood clots, stroke; endometrial cancer and uterine sarcoma in postmenopausal women | Osteoporosis and fractures; blood clots very rarely; they don’t cause uterine cancer |
Why aromatase inhibitors don’t work on their own before menopause: while the ovaries are active, they produce most of the estrogen, and an aromatase inhibitor can’t lower its level effectively. That’s why in younger women this drug is combined with “switching off” the ovaries.
Sometimes drugs are switched during treatment: for example, 2–3 years of tamoxifen followed by an aromatase inhibitor. If an aromatase inhibitor has to be stopped because of side effects, most oncologists switch the patient to tamoxifen to complete the planned course.
Ovarian suppression
In women who haven’t reached menopause, ovarian function can be suppressed:
- temporarily — with injections of gonadotropin-releasing hormone (GnRH) agonists, given regularly throughout treatment;
- permanently — by removing the ovaries (oophorectomy).
This is an artificial menopause with everything that comes with it: hot flashes, dryness of the mucous membranes, lower libido, a risk of bone loss. Ovarian suppression isn’t added for everyone, but depending on the risk of recurrence, age and other features of the tumor — the decision is made by the oncologist, often at a multidisciplinary team meeting.
How many years treatment lasts
The standard length of adjuvant hormone therapy is at least 5 years. When the risk of recurrence is higher, treatment may be extended — up to 10 years in total. According to the American Cancer Society (ACS), tamoxifen after surgery is usually taken for 5–10 years.
Why so long: hormone receptor-positive breast cancer can come back many years after surgery. I write about why this happens and how follow-up works in the article on cancer recurrence.
CDK4/6 inhibitors: when tablets are added to hormone therapy
CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) are targeted drugs that strengthen the effect of hormone therapy by blocking cancer cell division.
In metastatic cancer, any of them can be combined with an aromatase inhibitor or fulvestrant (a drug that breaks down the estrogen receptor), regardless of menopausal status. Women who haven’t reached menopause also have ovarian suppression.
After surgery, when the risk of recurrence is high, they are added to standard hormone therapy for a limited time:
- abemaciclib — for about 2 years, together with tamoxifen or an aromatase inhibitor, if the cancer has spread to the lymph nodes and the risk of recurrence is high;
- ribociclib — for about 3 years, together with an aromatase inhibitor, for stage II–III cancer with a high risk of recurrence.
Common side effects of these drugs are low white blood cell and neutrophil counts and fatigue; nausea, diarrhea and changes in liver tests can occur, and rarely lung inflammation. That’s why regular blood tests are needed while taking them.
Side effects and what to do about them
Most side effects of hormone therapy are signs of estrogen deficiency. Many of them can be reduced — and that is better than giving up treatment.
- Hot flashes and night sweats. The most common side effect. Layered clothing, a cool bedroom and avoiding alcohol and spicy food help. If hot flashes are disrupting your life, there are non-hormonal medicines — but with tamoxifen they need to be chosen carefully: some antidepressants make it less effective.
- Joint pain on aromatase inhibitors. Regular physical activity and painkillers help, and sometimes switching to another aromatase inhibitor or to tamoxifen. The ACS also mentions duloxetine and acupuncture.
- Bone loss. On aromatase inhibitors, bone density is checked regularly (a DEXA scan). If it falls, bone-strengthening drugs (bisphosphonates or denosumab), vitamin D and calcium are prescribed — as directed by your doctor.
- Vaginal dryness, lower libido. People are embarrassed to talk about it, but it can be helped: there are non-hormonal moisturizers. Any hormonal products for local use — only with your oncologist’s agreement.
On tamoxifen, tell your doctor straight away about any vaginal bleeding after menopause, and about pain, swelling and redness in a leg or sudden shortness of breath. For shortness of breath, chest pain, sudden weakness in an arm or leg or difficulty speaking, call your local emergency number (911 in the US, 999 in the UK, 112 in the EU).
Why it matters not to miss doses
Hormone therapy means one tablet a day for many years, and missed doses seem like a small thing. But the data say otherwise. In a large US study (almost 8,800 women), 31% of patients stopped hormone therapy early. Ten-year survival was 80.7% among those who continued treatment and 73.6% among those who stopped; among those who continued, results were better for women who took the drug regularly.
What helps you remember: take the tablet at the same time every day, link it to a daily routine (breakfast, brushing your teeth), set a phone reminder, use a weekly pill organizer. If you miss a dose, don’t take a double dose — ask your doctor what to do in that case with your particular drug.
If you are thinking about stopping treatment because of side effects, tell your oncologist honestly. There is often another option — switching drugs, adjusting supportive treatment, or taking a short break under medical supervision.
Pregnancy and contraception
Tamoxifen can harm an unborn baby, so pregnancy must be reliably prevented during treatment. According to Cancer Research UK, pregnancy should be avoided for at least 9 more months after stopping tamoxifen. Discuss in advance with your oncologist and gynecologist which method of contraception suits you: not all methods are appropriate for hormone receptor-positive cancer. If you do become pregnant, tell your doctor straight away.
If you want a child, that doesn’t necessarily mean giving up on your plans. In the international POSITIVE study, women who had received 18–30 months of hormone therapy took a planned break of up to 2 years to become pregnant and then resumed treatment. With about 6 years of follow-up, their risk of recurrence was no higher than in a comparable group, but the authors stress that this doesn’t mean a break is right for everyone, especially at high risk. This question should always be discussed with your oncologist in advance.
Questions to ask your oncologist
- Which drug have I been prescribed, and why this one?
- How many years is treatment planned for, and what would make it longer?
- Do I need ovarian suppression?
- Am I a candidate for adding a CDK4/6 inhibitor?
- How often should my bone density be checked, and which tests do I need?
- What should I do if I am planning a pregnancy?
If you have doubts about the choice of drug or the length of treatment, I can review your reports and hormone therapy plan in an online consultation — with a written summary afterwards.
Sources
- Hormone Therapy for Breast Cancer — National Cancer Institute (NCI), accessed 2026
- Hormone Therapy for Breast Cancer — American Cancer Society, accessed 2026
- Targeted Drug Therapy for Breast Cancer — American Cancer Society, accessed 2026
- Tamoxifen — Cancer Research UK, accessed 2026
- Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer — Hershman D. L. et al., Breast Cancer Research and Treatment, 2011
- POSITIVE Trial Update: Oncologic Outcomes Maintained After Pausing Endocrine Therapy for Pregnancy — The ASCO Post, 2026
Watch me explain this on video
Short videos on my Instagram (in Russian)
Frequently asked questions
This article is for information only and does not replace a consultation with your treating doctor. Decisions about tests and treatment are made by the doctor who looks after you.
